LOS ANGELES, - PHC (Prostate Health Cocktail), the over-the-counter prostate cancer treatment from OncoNatural Solutions, has been awarded a U.S. patent. An FDA-authorized clinical study showed the non-toxic dietary supplement achieves significant results for men with recurrent prostate cancer.
The study, presented at the American Society of Clinical Oncology (ASCO) 2012 Genitourinary Cancers Symposium, found that prostate specific antigen (PSA) stabilized in 83% of subjects with recurrent prostate cancer who took three PHC capsules daily. In nearly 30% of subjects with recurrent prostate cancer, PSA actually declined. Moreover, the study found no significant decline in subjects' testosterone levels, indicating that ED (erectile dysfunction) is not a side effect of PHC treatment.
Recurrent prostate cancer is indicated when PSA levels continue to rise following prostatectomy or radiation therapy. Approximately 30% of prostate cancer survivors develop recurrent prostate cancer. While the study provides clear evidence PHC is beneficial to men with recurrent prostate cancer, the supplement may also contribute to healthy outcomes for men diagnosed with enlarged prostate or early prostate disease.
Developed by respected oncologist and prostate cancer researcher Jacek Pinski, M.D., Ph.D., PHC contains EGCG from green tea extract, along with selenium, lycopene, genistein, daidzein, vitamin D3, vitamin E and saw palmetto fruit extract -- a group of minerals, herbs, vitamins and isoflavanoids shown to reduce the risk of prostate disease in men ages 40 and older. For men with enlarged prostate, the supplement has proven to be particularly effective at relieving the discomfort and frustration of urinary problems and erectile dysfunction.
"PHC is designed for use as a complement to existing prostate cancer treatments," Dr. Pinski stated. "The formula is based on extensive research, and evidence of its effectiveness continues to accumulate. The recent patent award reinforces the promise of this breakthrough dietary supplement and our commitment to forward-thinking treatment plans for men with recurrent prostate cancer."
PR Newswire